Xenetic Biosciences opens corporate headquarters and R&D facility in Massachusetts

Xenetic, in collaboration with the Massachusetts Life Sciences Center (MLSC) and the Massachusetts Biotechnology Council (MassBio), will host a grand opening and ribbon cutting ceremony to celebrate the completion of the company’s relocation of its global headquarters to Lexington from London, UK.

The relocation decision follows the March 2011 visit to the UK by Governor Deval Patrick and a delegation of state leaders from industry, academia and government to promote mutually beneficial collaborations. The first discussion with Xenetic took place during that trade mission. The company currently has seven employees in Lexington with plans to grow to 14 by the end of 2014.

Xenetic CEO Scott Maguire noted the opening of the company’s new corporate headquarters in Lexington marks an important new phase in the company’s 17 year history.

"Moving our development operations to the Massachusetts biotech corridor is an important step in our transition to becoming an innovative biopharmaceutical company based and publicly listed in the U.S. We believe that we are much more strongly positioned to execute on our mission to develop and commercialize leading next-generation biologic drugs and novel oncology therapeutics," Maguire added.

The company’s new corporate headquarters is located at 99 Hayden Avenue, Suite 230, Lexington, Massachusetts 02421.